文献速递传染病防控与疫情报告卫生政策与健康促进

格鲁吉亚丙型肝炎消除规划的中期效果评估:一项模型研究

Interim effect evaluation of the hepatitis C elimination programme in Georgia: a modelling study.
PubMed 文献 · Lancet Glob Health · 2019-12-18

格鲁吉亚2015年启动消除丙型肝炎国家规划,目标2020年患病率降低90%。本研究建立传播模型,校准至注射吸毒人群行为学调查(1998-2015年)和2015年全国调查数据,评估直接抗病毒治疗的中期效果。模型预测2015年5月至2019年2月治疗54313例使成人慢性丙肝患病率中位降低37%,但按当前治疗率到2020年底仅降低51%,需每月治疗4144例才能达到90%目标。

要点

  • 2015年5月至2019年2月共治疗54313例,2017年中期以来每月约治疗1000例。
  • 模型预测患病率中位降低37%(95%可信区间30-44),慢性丙肝发病率降低37%(29-44),死亡率降低14%(3-30)。
  • 若维持每月治疗1000例,到2020年底患病率降低51%(42-61),发病率降低51%(40-62),难以达到90%目标。

核心结论

  • 格鲁吉亚丙型肝炎消除规划已实现大幅治疗扩展,减轻了慢性丙型肝炎负担,但除非治疗规模显著扩大,该国不太可能实现2020年消除目标。

研究设计与样本

  • 建立丙型肝炎传播模型,校准至注射吸毒人群行为学调查(1998-2015年)和2015年全国调查数据,预测2015年5月1日至2019年2月28日直接抗病毒治疗的效果,以及维持当前治疗率至2020年底的效果。

主要发现

  • 2015年5月1日至2019年2月28日共治疗54313例患者,2017年中期以来每月约治疗1000例。
  • 与2015年相比,模型预测这些治疗使成人慢性丙型肝炎患病率中位降低37%(95%可信区间30-44),慢性丙型肝炎发病率降低37%(29-44),慢性丙型肝炎死亡率降低14%(3-30)。
  • 模型预测预防了3516例(1842-6250)新发感染,避免了252例(134-389)慢性丙型肝炎相关死亡。
  • 若维持每月治疗1000例,预测到2020年底患病率降低51%(42-61),发病率降低51%(40-62)。
  • 要达到2020年患病率降低90%的目标,治疗率必须增至每月4144例(2963-5322)开始治疗的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Georgia has a high prevalence of hepatitis C, with 5·4% of adults chronically infected. On April 28, 2015, Georgia launched a national programme to eliminate hepatitis C by 2020 (90% reduction in prevalence) through scaled-up treatment and prevention interventions. We evaluated the interim effect of the programme and feasibility of achieving the elimination goal. METHODS: We developed a transmission model to capture the hepatitis C epidemic in Georgia, calibrated to data from biobehavioural surveys of people who inject drugs (PWID; 1998-2015) and a national survey (2015). We projected the effect of the administration of direct-acting antiviral treatments until Feb 28, 2019, and the effect of continuing current treatment rates until the end of 2020. Effect was estimated in terms of the relative decrease in hepatitis C incidence, prevalence, and mortality relative to 2015 and of the deaths and infections averted compared with a counterfactual of no treatment over the study period. We also estimated treatment rates needed to reach Georgia's elimination target. FINDINGS: From May 1, 2015, to Feb 28, 2019, 54 313 patients were treated, with approximately 1000 patients treated per month since mid 2017. Compared with 2015, our model projects that these treatments have reduced the prevalence of adult chronic hepatitis C by a median 37% (95% credible interval 30-44), the incidence of chronic hepatitis C by 37% (29-44), and chronic hepatitis C mortality by 14% (3-30) and have prevented 3516 (1842-6250) new infections and averted 252 (134-389) deaths related to chronic hepatitis C. Continuing treatment of 1000 patients per month is predicted to reduce prevalence by 51% (42-61) and incidence by 51% (40-62), by the end of 2020. To reach a 90% reduction by 2020, treatment rates must increase to 4144 (2963-5322) patients initiating treatment per month. INTERPRETATION: Georgia's hepatitis C elimination programme has achieved substantial treatment scale-up, which has reduced the burden of chronic hepatitis C. However, the country is unlikely to meet its 2020 elimination target unless treatment scales up considerably. FUNDING: CDC Foundation, National Institute for Health Research, National Institutes of Health.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Walker JG, Kuchuloria T, Sergeenko D, et al. Interim effect evaluation of the hepatitis C elimination programme in Georgia: a modelling study. Lancet Glob Health. 2019. PMID: 31864917. doi:10.1016/S2214-109X(19)30483-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。